<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665154</url>
  </required_header>
  <id_info>
    <org_study_id>CMAS825A02101</org_study_id>
    <nct_id>NCT04665154</nct_id>
  </id_info>
  <brief_title>A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers</brief_title>
  <acronym>MAS-FIH</acronym>
  <official_title>A First-in-human, Randomized, Subject-blinded, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825&#xD;
      in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 14, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>up to day 253</time_frame>
    <description>To assess the safety and tolerability of single i.v./s.c. doses of MAS825</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentrations of anti-MAS825 antibodies</measure>
    <time_frame>up to day 197</time_frame>
    <description>To assess immunogenicity (IG) of MAS825</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>up to day 197</time_frame>
    <description>Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: Time to reach maximum concentration [Tmax]</measure>
    <time_frame>up to day 197</time_frame>
    <description>Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: AUClast</measure>
    <time_frame>up to day 197</time_frame>
    <description>The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: AUCinf</measure>
    <time_frame>up to day 197</time_frame>
    <description>The AUC from time zero to infinity (mass x time x volume-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: T1/2</measure>
    <time_frame>up to day 197</time_frame>
    <description>The elimination half-life associated with the terminal slope (lambda_z) of a semi logarithmic concentration-time curve (time). Use qualifier for other half-lives</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: CL</measure>
    <time_frame>up to day 197</time_frame>
    <description>CL is the systemic (or total body) clearance from plasma (or serum or blood) following intravenous administration [volume / time]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: Vz</measure>
    <time_frame>up to day 197</time_frame>
    <description>Vz is the volume of distribution during the terminal elimination phase following intravenous administration [volume]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: Vz/F</measure>
    <time_frame>up to day 197</time_frame>
    <description>Vz/F is the apparent volume of distribution during the terminal elimination phase following s.c. administration (associated with λz) (volume)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: Vss</measure>
    <time_frame>up to day 197</time_frame>
    <description>Vss is the volume of distribution at steady state following intravenous administration [volume]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of MAS825: CL/F</measure>
    <time_frame>up to day 197</time_frame>
    <description>CL/F is the apparent systemic (or total body) clearance from plasma (or serum or blood) following s.c. administration [volume / time]</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>MAS825 dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single i.v. dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAS825 dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single s.c. dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single i.v. dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo dose B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single s.c. dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAS825</intervention_name>
    <description>single dose i.v. and s.c.</description>
    <arm_group_label>MAS825 dose A</arm_group_label>
    <arm_group_label>MAS825 dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single dose i.v. and s.c.</description>
    <arm_group_label>Placebo dose A</arm_group_label>
    <arm_group_label>Placebo dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Healthy male and female subjects 18 to 45 years of age included, and in good health as&#xD;
        determined by past medical history, physical examination, vital signs, electrocardiogram,&#xD;
        and laboratory tests at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant&#xD;
&#xD;
          -  A history of ongoing, chronic or recurrent infectious disease, or evidence of&#xD;
             tuberculosis infection as defined by a positive QuantiFERON TB-Gold test&#xD;
&#xD;
          -  Fasting LDL &gt; 160 mg/dL, at screening.&#xD;
&#xD;
          -  Subjects in cohorts D1 and D2 (Japanese cohorts) must be of first to third generation&#xD;
             Japanese ethnic origin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mere Way</city>
        <state>Nottingham</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

